SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

0.38USD0.00 (0.00%)Delayed as of 17 May 2024, 12:50 pm ET

Market Summary

USD0.380.00

Delayedas of 17 May 2024, 12:50 pm

0.00%

SNTI Stock Price

View Fullscreen

SNTI RSI Chart

SNTI Valuation

Market Cap

17.4M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

6.79

Price/Free Cashflow

-0.33

SNTI Price/Sales (Trailing)

SNTI Profitability

Return on Equity

-208.2%

Return on Assets

-114.29%

Free Cashflow Yield

-306.66%

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

SNTI Earnings

Earnings (TTM)

-116.8M

Earnings Growth (Yr)

35.31%

Earnings Growth (Qtr)

82.96%

Breaking Down SNTI Revenue

52 Week Range

0.41

(Low)(High)

Last 7 days

2.7%

Last 30 days

26.7%

Last 90 days

-7.3%

How does SNTI drawdown profile look like?

SNTI Financial Health

Current Ratio

5.79

SNTI Investor Care

Shares Dilution (1Y)

3.59%

Diluted EPS (TTM)

-1.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.5M	4.0M	2.6M	2.6M
2022	3.8M	4.4M	5.0M	4.3M
2021	1.1M	1.7M	2.2M	2.8M
2020	0	0	0	566.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Senti Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	rajangam kanya	acquired	-	-	101,000	chief medical & devt. officer
Feb 01, 2024	lu timothy k	acquired	-	-	306,000	ceo and president
Feb 01, 2024	knobelman deborah	acquired	-	-	101,000	chief financial officer
Oct 03, 2022	knobelman deborah	acquired	-	-	30,000	chief financial officer
Jun 08, 2022	epstein david r	acquired	-	-	112,519	-
Jun 08, 2022	farokhzad omid	acquired	-	-	5,750,000	-
Jun 08, 2022	farokhzad omid	acquired	2,500,000	10.00	250,000	-
Jun 08, 2022	farokhzad omid	sold	-	-	-4,518,100	-
Jun 08, 2022	dynamics sponsor llc	acquired	-	-	5,750,000	-
Jun 08, 2022	dynamics sponsor llc	sold	-	-	-6,465,500	-

Which funds bought or sold SNTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-11,061	14,745	-%
May 15, 2024	MORGAN STANLEY	new	-	603	603	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-95.4	-3,368	91.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	3,210	3,210	-%
May 15, 2024	NEA Management Company, LLC	unchanged	-	-1,252,160	1,669,100	0.10%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-7.48	-4,485	5,029	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	226	16,400	35,304	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-41,020	54,680	-%
May 15, 2024	CITADEL ADVISORS LLC	added	80.78	949	29,793	-%
May 14, 2024	TORONTO DOMINION BANK	new	-	14.00	14.00	-%

Are Funds Buying or Selling SNTI?

Are funds buying SNTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNTI

No. of Funds

Unveiling Senti Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	woodline partners lp	0%	0	SC 13G/A

Recent SEC filings of Senti Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	3	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report

Peers (Alternatives to Senti Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Senti Biosciences, Inc. News

Latest updates

Senti Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-	-	-	338	937	1,286	59.00	1,766	1,358	1,104	793	1,103	793	72.00	-
Operating Expenses	16.1%	16,301	14,040	44,214	20,572	21,120	15,359	16,514	23,129	12,862	11,678	12,526	9,789	9,214	-
S&GA Expenses	-100.0%	-	8,814	9,431	9,620	9,802	9,453	9,995	13,882	5,259	5,269	7,116	4,554	4,311	-
R&D Expenses	77.2%	8,779	4,955	9,092	10,952	11,318	5,907	6,519	9,247	7,603	6,409	5,410	5,235	4,903	-
Net Income	83.0%	-12,111	-71,058	-14,923	-18,697	-18,722	-58,210	-16,640	-11,552	-11,808	-10,904	-11,406	-12,007	-21,002	-
Net Income Margin	5.4%	-45.60*	-48.18*	-42.20*	-27.74*	-23.53*	-22.91*	-10.14*	-10.48*	-12.16*	-20.04*	-8.98*	-11.94*	-17.82*	-35.09*
Free Cashflow	-66.1%	-11,697	-7,041	-17,237	-17,344	-22,811	-17,539	-24,337	-16,955	-17,439	-15,956	-9,737	-1,354	-8,571	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4
Assets	-14.5%	102	119	132	144	161	181	189	202	92.00	97.00	232	232	232	171	110	48.00
Current Assets	-21.8%	56.00	71.00	79.00	63.00	81.00	103	120	144	45.00	60.00	2.00	2.00	2.00	-	-	32.00
Cash Equivalents	-22.8%	28.00	36.00	39.00	37.00	32.00	58.00	115	140	38.00	59.00	74.00	83.00	2.00	26.00	-	31.00
Net PPE	-3.9%	24.00	25.00	26.00	59.00	59.00	51.00	47.00	36.00	24.00	12.00	-	-	-	-	-	3.00
Liabilities	-12.3%	46.00	53.00	49.00	46.00	49.00	54.00	49.00	48.00	42.00	36.00	8.00	8.00	8.00	11.00	14.00	17.00
Current Liabilities	-24.2%	10.00	13.00	10.00	10.00	13.00	18.00	16.00	18.00	18.00	15.00	0.00	0.00	0.00	-	-	5.00
Shareholder's Equity	-16.2%	56.00	67.00	83.00	97.00	112	127	140	154	-	-111	-	5.00	-	0.00	-	-
Retained Earnings	-5.0%	-256	-244	-225	-210	-192	-173	-155	-138	-126	-115	-6.52	-6.23	-6.00	0.00	0.00	-59.76
Additional Paid-In Capital	0.4%	313	311	309	308	304	301	295	293	5.00	4.00	-	-	-	0.00	0.00	1.00
Accumulated Depreciation	14.9%	7.00	6.00	5.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	-	-	-	-	-	1.00
Shares Outstanding	0.1%	46.00	46.00	44.00	44.00	44.00	44.00	43.00	13.00	3.00	3.00	3.00	3.00	-	15.00	5.00	14.00
Float	-100.0%	-	30.00	-	24.00	-	-	-	75.00	-	-	-	229	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4
Cashflow From Operations	-66.0%	-11,682	-7,037	-15,379	-13,675	-16,304	-9,006	-10,136	-5,695	-10,059	-11,971	-8,805	-934	-8,365	-	-
Share Based Compensation	-39.1%	1,258	2,064	409	3,434	3,763	4,216	2,290	9,225	661	735	626	562	372	-	-
Cashflow From Investing	-114.9%	-15.00	101	21,142	18,331	-9,497	-49,118	-14,201	-11,260	-7,380	-	-	-230,000	-206	-	-
Cashflow From Financing	-100.0%	-	556	-23.00	281	-35.00	876	-485	118,615	-455	-	-	232,032	3,558	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNTI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Contract revenue	$ 0	$ 1,036,000
Grant income	0	250,000
Total revenue	0	1,286,000
Operating expenses
Research and development (included related party cost of $3,632 and $—, respectively)	8,779,000	7,059,000
General and administrative	7,522,000	9,191,000
Total operating expenses	16,301,000	16,250,000
Loss from operations	(16,301,000)	(14,964,000)
Other income (expense)
Interest income, net	331,000	1,061,000
Change in fair value of contingent earnout liability	0	59,000
GeneFab sublease income - related party	1,461,000	0
Other income (expense)	0	(8,000)
Total other income, net	4,190,000	1,112,000
Net loss from continuing operations	(12,111,000)	(13,852,000)
Net loss from discontinued operations	0	(4,870,000)
Net loss	(12,111,000)	(18,722,000)
Other comprehensive gain (loss)
Unrealized gain on investments	0	2,000
Comprehensive loss	$ (12,111,000)	$ (18,720,000)
Net loss per share, basic and diluted
Net loss per share from continuing operations, basic (in dollars per share)	$ (0.26)	$ (0.31)
Net loss per share from continuing operations, diluted (in dollars per share)	(0.26)	(0.31)
Net income (loss) per share from discontinued operations, basic (in dollars per share)	0.00	(0.11)
Net loss per share from discontinued operations, diluted (in dollars per share)	0	(0.11)
Net loss per share, basic (in dollars per share)	(0.26)	(0.42)
Net loss per share, diluted (in dollars per share)	$ (0.26)	$ (0.42)
Weighted-average shares outstanding, basic (in shares)	45,708,601	44,070,974
Weighted-average shares outstanding, diluted (in shares)	45,708,601	44,070,974
GeneFab Note Receivable
Other income (expense)
Change in fair value	$ 29,000	$ 0
GeneFab Economic Share
Other income (expense)
Change in fair value	55,000	0
GeneFab Option
Other income (expense)
Change in fair value	$ 2,314,000	$ 0

SNTI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 23,723	$ 35,926
Total current assets	55,666	71,200
Restricted cash	4,028	3,522
GeneFab receivable - related party, net of current portion	383	1,119
Property and equipment, net	24,354	25,338
Operating lease right-of-use assets	15,797	16,274
GeneFab Economic Share - related party	1,871	1,816
Other long-term assets	86	215
Total assets	102,185	119,484
Liabilities and Stockholders’ Equity
Accounts payable	1,624	1,250
Finance lease liabilities, current portion	100	97
Early exercise liability, current portion	111	135
GeneFab sublease deferred income - related party	862	989
Accrued expenses and other current liabilities	2,734	5,927
Operating lease liabilities	4,178	4,031
Current liabilities of discontinued operations	0	243
Total current liabilities	9,609	12,672
Operating lease liabilities, net of current portion	32,445	33,538
Contingent earnout liability	20	20
GeneFab Option - related party	4,017	6,331
Early exercise liability, net of current portion	0	10
Total liabilities	46,091	52,571
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 45,712,821 and 45,700,161 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	312,544	311,252
Accumulated other comprehensive income	0	0
Accumulated deficit	(256,455)	(244,344)
Total stockholders’ equity	56,094	66,913
Total liabilities and stockholders’ equity	102,185	119,484
Nonrelated Party
Assets
Accounts receivable	76	112
Prepaid expenses and other current assets	2,720	2,783
Related Party
Assets
Accounts receivable	17,847	17,592
Prepaid expenses and other current assets	$ 11,300	$ 14,787

About Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

CEO	Dr. Timothy K. Lu M.D., Ph.D.
WEBSITE	sentibio.com
INDUSTRY	Biotechnology
EMPLOYEES	122

Senti Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Senti Biosciences, Inc.? What does SNTI stand for in stocks?

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Senti Biosciences, Inc. (SNTI)?

As of Thu May 16 2024, market cap of Senti Biosciences, Inc. is 17.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers. The fair value of Senti Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Senti Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Senti Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNTI is over valued or under valued. Whether Senti Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Senti Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNTI.

What is Senti Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SNTI's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 6.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.